These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 6628500

  • 1. Cardiocirculatory effects of moclobemide (Ro 11-1163), a new reversible, a short-acting MAO-inhibitor with preferential type A inhibition, in healthy volunteers and depressive patients.
    Gasic S, Korn A, Eichler HG, Oberhummer I, Zapotoczky HG.
    Eur J Clin Pharmacol; 1983; 25(2):173-7. PubMed ID: 6628500
    [Abstract] [Full Text] [Related]

  • 2. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers.
    Illi A, Sundberg S, Ojala-Karlsson P, Scheinin M, Gordin A.
    Clin Pharmacol Ther; 1996 Apr; 59(4):450-7. PubMed ID: 8612391
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.
    Dingemanse J, Guentert T, Gieschke R, Stabl M.
    J Cardiovasc Pharmacol; 1996 Dec; 28(6):856-61. PubMed ID: 8961085
    [Abstract] [Full Text] [Related]

  • 6. Comparative investigation of the effect of moclobemide and toloxatone on monoamine oxidase activity and psychometric performance in healthy subjects.
    Dingemanse J, Berlin I, Payan C, Thiede HM, Puech AJ.
    Psychopharmacology (Berl); 1992 Dec; 106 Suppl():S68-70. PubMed ID: 1546145
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of oral moclobemide in healthy human subjects and effects on MAO-activity in platelets and excretion of urine monoamine metabolites.
    Wiesel FA, Raaflaub J, Kettler R.
    Eur J Clin Pharmacol; 1985 Dec; 28(1):89-95. PubMed ID: 3987791
    [Abstract] [Full Text] [Related]

  • 8. The effects of moclobemide on the pharmacokinetics of the 5-HT1B/1D agonist rizatriptan in healthy volunteers.
    Van Haarst AD, Van Gerven JM, Cohen AF, De Smet M, Sterrett A, Birk KL, Fisher AL, De Puy ME, Goldberg MR, Musson DG.
    Br J Clin Pharmacol; 1999 Aug; 48(2):190-6. PubMed ID: 10417495
    [Abstract] [Full Text] [Related]

  • 9. Tyramine pressor response with moclobemide--a reversible monoamine oxidase inhibitor.
    Tiller JW, Maguire KP, Davies BM.
    Psychiatry Res; 1987 Nov; 22(3):213-20. PubMed ID: 3432450
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological profile of moclobemide, a short-acting and reversible inhibitor of monoamine oxidase type A.
    Burkard WP, Bonetti EP, Da Prada M, Martin JR, Polc P, Schaffner R, Scherschlicht R, Hefti F, Müller RK, Wyss PC.
    J Pharmacol Exp Ther; 1989 Jan; 248(1):391-9. PubMed ID: 2913284
    [Abstract] [Full Text] [Related]

  • 11. Inhibition of monoamine oxidase by moclobemide: effects on monoamine metabolism and secretion of anterior pituitary hormones and cortisol in healthy volunteers.
    Koulu M, Scheinin M, Kaarttinen A, Kallio J, Pyykkö K, Vuorinen J, Zimmer RH.
    Br J Clin Pharmacol; 1989 Feb; 27(2):243-55. PubMed ID: 2469451
    [Abstract] [Full Text] [Related]

  • 12. Comparison of the pressor effect of tyramine after treatment with phenelzine and moclobemide in healthy male volunteers.
    Simpson GM, Gratz SS.
    Clin Pharmacol Ther; 1992 Sep; 52(3):286-91. PubMed ID: 1526086
    [Abstract] [Full Text] [Related]

  • 13. [Comparison of the new MAO-A inhibitors moclobemide, brofaromine and toloxatone with tranylcypromine in an animal experiment: significance for clinical practice].
    Da Prada M, Keller HH, Kettler R.
    Psychiatr Prax; 1989 Aug; 16 Suppl 1():18-24. PubMed ID: 2587673
    [Abstract] [Full Text] [Related]

  • 14. Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.
    Versiani M, Nardi AE, Figueira IL, Stabl M.
    Acta Psychiatr Scand Suppl; 1990 Aug; 360():24-8. PubMed ID: 2123366
    [Abstract] [Full Text] [Related]

  • 15. Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.
    Scheinin M, Koulu M, Vakkuri O, Vuorinen J, Zimmer RH.
    Prog Neuropsychopharmacol Biol Psychiatry; 1990 Aug; 14(1):73-82. PubMed ID: 2300680
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the effects of moclobemide and selegiline on tyramine-evoked mydriasis in man.
    Bitsios P, Langley RW, Tavernor S, Pyykkö K, Scheinin M, Szabadi E, Bradshaw CM.
    Br J Clin Pharmacol; 1998 Jun; 45(6):551-8. PubMed ID: 9663810
    [Abstract] [Full Text] [Related]

  • 17. Relationship between tyramine potentiation and monoamine oxidase (MAO) inhibition: comparison between moclobemide and other MAO inhibitors.
    Zimmer R.
    Acta Psychiatr Scand Suppl; 1990 Jun; 360():81-3. PubMed ID: 2248084
    [Abstract] [Full Text] [Related]

  • 18. Potentiation of the pressor effect of intravenously administered tyramine during moclobemide treatment.
    Zimmer R, Fischbach R, Breuel HP.
    Acta Psychiatr Scand Suppl; 1990 Jun; 360():76-7. PubMed ID: 2248082
    [Abstract] [Full Text] [Related]

  • 19. Pre-clinical pharmacology of moclobemide. A review of published studies.
    Burkard WP, Da Prada M, Keller HH, Kettler R, Haefely W.
    Br J Psychiatry Suppl; 1989 Oct; (6):84-8. PubMed ID: 2695131
    [Abstract] [Full Text] [Related]

  • 20. Effect of a novel monoamine-oxidase inhibitor, moclobemide on the sensitivity to intravenous tyramine and norepinephrine in humans.
    Cusson JR, Goldenberg E, Larochelle P.
    J Clin Pharmacol; 1991 May; 31(5):462-7. PubMed ID: 2050833
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.